Quanterix to Participate in Upcoming Investor Conferences

Quanterix Corporation (Nasdaq: QTRX), a pioneering leader in healthcare innovation focusing on biomarker detection, recently announced its participation in two prominent investor conferences scheduled for March 2026. The executive leadership team will be featured in a fireside chat format, coupled with one-on-one meetings, allowing investors a closer look at the company's strategic vision and advancements.

The 46th Annual TD Cowen Healthcare Conference will take place on Wednesday, March 4, 2026, at 11:50 am ET, followed by the Leerink Global Healthcare Conference on Monday, March 9, 2026, at 1:00 pm ET. Interested parties can tune in to live and recorded webcasts of these discussions through the Investors section of Quanterix's website.

Quanterix is renowned for its ultra-sensitive biomarker detection capabilities, significantly enhancing research, diagnostics, and drug development processes. Utilizing its proprietary Simoa® technology, Quanterix enables researchers to detect and quantify biomarkers in blood and other fluids at unprecedented sensitivity levels, surpassing traditional methods. The company boasts an extensive track record with approximately 6,000 peer-reviewed publications, establishing it as a trusted entity within the scientific community for nearly two decades.

In a notable expansion of its capabilities, Quanterix acquired Akoya Biosciences in 2025, thus integrating multiplexed tissue imaging with single-cell resolution into its offerings. This acquisition enhances the company's portfolio, providing a comprehensive platform that connects biological research across both blood and tissue. As Quanterix continues to advance precision medicine from discovery to diagnostics, it remains committed to transforming healthcare through innovative biomarker breakthroughs.

For further information, stakeholders are encouraged to visit Quanterix's official website at www.quanterix.com.

Quanterix Corporation (Nasdaq: QTRX) is poised to leverage upcoming investor conferences, a strategic move that could enhance its market presence and investor engagement. Scheduled for March 2026, the company will participate in two significant events: the 46th Annual TD Cowen Healthcare Conference and the Leerink Global Healthcare Conference. Both will feature fireside chats and one-on-one meetings, allowing the executive leadership team to articulate the company’s vision and the transformative impact of its Simoa® technology on healthcare.

Quanterix stands out in the biomarker detection space with its ultra-sensitive detection methods, providing an edge in oncology, neurology, and other critical areas of disease research. The recent acquisition of Akoya Biosciences enhances its portfolio, adding capabilities in multiplexed tissue imaging. This positions Quanterix as a pivotal player in precision medicine, connecting insights across both blood and tissue functionalities.

As the biotech sector evolves, investor interest is naturally gravitating toward companies that showcase innovation and an ability to address pressing healthcare challenges. Participation in these conferences offers Quanterix a dual opportunity: to attract potential investors and to solidify its relationships with existing stakeholders. By engaging in live and recorded webcasts, Quanterix ensures that its messaging penetrates broad audiences, enhancing transparency and shareholder confidence.

For prospective investors, tracking Quanterix's developments during these conferences is imperative. Analysts should closely listen to discussions around product pipeline advancements, strategic plans post-Akoya acquisition, and insights gathered from key market trends. Given the rising demand for precision medicine, Quanterix's innovative approach could signify significant long-term growth. Investors should monitor QTRX for potential entry points, especially in the wake of these insightful engagements. This proactive approach could yield dividends as Quanterix continues to reshape the landscape of biomarker detection and diagnostics.